3-year follow-up study of secukinumab treatment in patients with active Ankylosing Spondylitis

Phase 1

• Conditions: Ankylosing spondylitis; Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]; MedDRA version: 19.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

• Registration Number: EUCTR2013-001089-40-NL
• Lead Sponsor: ovartis Pharma Services AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-09-26
• Last Update Posted: 7 May 2018

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

- Patients having completed the core study CAIN457F2305.
- Indication for treatment extension

Other protocol-defined inclusion criteria may apply.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 285
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 15

Exclusion Criteria

- History of hypersensitivity to secukinumab or to any drug of similar chemical classes.
- Use of any investigational drug other than secukinumab during the core study CAIN457F2305.

Other protocol-defined exclusion criteria may apply.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified